MarketInOut Stock Screener Log In | Sign Up

CEL-SCI Corp

NYSE • Healthcare • Biotechnology • Quote as of 11/20/2026
CEL-SCI Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization21.66 mln
Float16.37 mln
Earnings Date11/14/2026

Piotroski F-Score

3 / 9
Below average

Relative Strength

10 / 100
Significantly lagging

Debt / Equity

0.72
Moderate leverage

ROE

-219
Deeply negative

ROA

-103
Deeply negative

Business Description

CEL-SCI Corporation is a US-based biotechnology company focused on developing treatments that harness the body's own immune system to fight cancer and other serious diseases. Its most advanced therapy, Multikine, has completed large-scale clinical trials as a potential treatment for certain head and neck cancers, and is being commercialized in the Middle East through a partnership with a Saudi Arabian pharmaceutical company. The company is also advancing its LEAPS technology, a patented approach to activating the immune system against a broad range of conditions including infections, autoimmune disorders, and cancer. Founded in 1983 and headquartered in Vienna, Virginia, CEL-SCI continues to develop several early-stage product candidates targeting rheumatoid arthritis.

Key Fundamentals

EPS-1.59
ROE-219
ROIC-116
ROA-103
Interest Cover-50.19
EBITDA, mln-18.43
EV / EBITDA-1.59
EV / EBIT-1.32

Quote Details

Last 1.21
Change -0.26 (-17.69%)
Open 1.54
Volume 878,999
Turnover 1,063,589
Average Volume 287,893

Financial Ratios

Leverage Ratio1.95
Current Ratio1.48
Price / Book1.77
Price / Tangible Book1.77
Debt / Equity0.72
PEG Ratio1.12

Financial Strength

Piotroski F-Score 3 / 9
Short Ratio2.57
Short % of Float4.14

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -5.47% 57 / 100   
1 Month -24.84% 8 / 100   
2 Months -21.94% 20 / 100   
6 Months -14.79% 26 / 100   
1 Year -80.55% 2 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog